Longeveron, Inc. (LGVN)
6.75
-0.05
(-0.74%)
USD |
NASDAQ |
Aug 28, 16:00
6.75
0.00 (0.00%)
After-Hours: 17:48
Longeveron Enterprise Value : 12.07M for Aug. 27, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 27, 2026 | 12.07M |
| August 26, 2026 | 12.81M |
| August 25, 2026 | 12.07M |
| August 24, 2026 | 17.08M |
| August 21, 2026 | 17.30M |
| August 20, 2026 | 16.77M |
| August 19, 2026 | 16.59M |
| August 18, 2026 | 15.47M |
| August 17, 2026 | 16.51M |
| August 14, 2026 | 13.97M |
| August 13, 2026 | 12.63M |
| August 12, 2026 | 14.19M |
| August 11, 2026 | 12.46M |
| August 10, 2026 | 13.86M |
| August 07, 2026 | 14.80M |
| August 06, 2026 | 15.04M |
| August 05, 2026 | 13.57M |
| August 04, 2026 | 14.04M |
| August 03, 2026 | 13.72M |
| July 31, 2026 | 12.75M |
| July 30, 2026 | 11.92M |
| July 29, 2026 | 9.377M |
| July 28, 2026 | 9.577M |
| July 27, 2026 | 9.878M |
| July 24, 2026 | 9.535M |
| Date | Value |
|---|---|
| July 23, 2026 | 9.764M |
| July 22, 2026 | 10.38M |
| July 21, 2026 | 9.903M |
| July 20, 2026 | 9.605M |
| July 17, 2026 | 10.23M |
| July 16, 2026 | 9.960M |
| July 15, 2026 | 10.66M |
| July 14, 2026 | 10.24M |
| July 13, 2026 | 10.52M |
| July 10, 2026 | 11.91M |
| July 09, 2026 | 11.14M |
| July 08, 2026 | 10.90M |
| July 07, 2026 | 10.56M |
| July 06, 2026 | 11.11M |
| July 02, 2026 | 12.41M |
| July 01, 2026 | 13.63M |
| June 30, 2026 | 12.80M |
| June 29, 2026 | 6.841M |
| June 26, 2026 | 7.013M |
| June 25, 2026 | 7.429M |
| June 24, 2026 | 7.767M |
| June 23, 2026 | 9.614M |
| June 22, 2026 | 9.626M |
| June 18, 2026 | 10.23M |
| June 17, 2026 | 10.85M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 12.28B |
| Oncolytics Biotech, Inc. | 102.27M |
| Sangamo Therapeutics, Inc. | 55.30M |
| Sarepta Therapeutics, Inc. | 2.538B |
| Anixa Biosciences, Inc. | 107.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.073M |
| Revenue (Quarterly) | 0.287M |
| Total Expenses (Quarterly) | 6.36M |
| EPS Diluted (Quarterly) | -1.936 |
| Gross Profit Margin (Quarterly) | -13.59% |
| Profit Margin (Quarterly) | -2.12K% |
| Earnings Yield | -150.4% |
| Normalized Earnings Yield | -150.38 |